一分钟看懂
这是一项关于癌症的III 期研究，登记的药物或干预包括Ipatasertib；Tiragolumab；Atezolizumab；Tiragolumab and Atezolizumab；Bevacizumab；Entrectinib；Inavolisib；Divarasib，当前状态为招募中。登记地点显示中国武汉、XI 'an City, Shaanxi Province、上海、北京等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Ipatasertib；Tiragolumab；Atezolizumab；Tiragolumab and Atezolizumab；Bevacizumab；Entrectinib；Inavolisib；Divarasib · III 期
登记条件中文摘要
年龄范围：登记摘要未给出明确年龄范围
登记的基本范围为不限性别，年龄登记摘要未给出明确年龄范围；以下仅摘录5项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出6项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology · 武汉
- First Affiliated Hospital of Medical College of Xi'an Jiaotong University · XI 'an City, Shaanxi Province
- Fudan University Shanghai Cancer Center · 上海
- Beijing Cancer Hospital · 北京
- the First Hospital of Jilin University · 长春
- West China Hospital of Sichuan University · 成都
- Cancer Center of Guangzhou Medical University · 广州
- Nanfang Hospital, Southern Medical University · 广州
- Zhejiang People's Hospital · 杭州
- Sir Run Run Shaw Hospital Zhejiang University · 杭州
- Zhejiang Cancer Hospital · 杭州
- Harbin Medical University Cancer Hospital · 哈尔滨
- The Second Affiliated Hospital of Anhui Medical University · 合肥
- Meizhou People's Hospital · 梅州
- The 1st Affiliated Hospital of Nanchang Unversity · 南昌
- Jiangsu Province Hospital of Chinese Medicine · 南京
- Fudan University Shanghai Cancer Center · 上海
- Shanghai Geriatric Medical Center · 上海
- Tianjin Cancer Hospital · 天津
- First Affiliated Hospital of Medical College of Xi'an Jiaotong University · 西安
- The First Affiliated Hospital of Xiamen University · 厦门
- The First Affiliated Hospital of Xinxiang Medical University · 新乡
- Henan Cancer Hospital · 郑州
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Eligible for continuing Roche IMP-based therapy at the time of roll-over from the parent study, as per the parent study protocol OR
- * Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study protocol, with no access to commercially available comparator agent
- * First dose of study treatment in this extension study will be received within 7 days of the treatment interruption window allowed by the parent study
- * Continue to benefit from the Roche IMP-based therapy or comparator at the time of roll-over from the parent study as assessed by the investigator
- * Ability to comply with the extension study protocol, per Investigator's judgement
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05862285；登记信息更新于 2026-10-02；本站同步于 2026-10-08。